Logo
  • Technology
  • Products
  • Market
  • About us
  • News
    • Regulatory news
  • Investor relations
  • Svenska
martin

New patent for IntelliGel

on the way in the EU

2018-10-02


Redwood Pharma

We develop ophthalmic drugs that address major medical needs. We focus on early-stage clinical development. Our long-term strategy is to enter into licence agreements with other drug companies who will in turn introduce products for the global market.

  • Welcome
  • Technology
  • Products
  • Market
  • About us
  • News
    • Regulatory news
  • Investor relations
    • Reports
    • Presentations
  • Privacy Policy

Contact

Martin Vidaeus – CEO
070-232 29 29
martin.vidaeus@redwoodpharma.com

Ringvägen 100E, floor 9
118 60 Stockholm, Sweden

Logo

Spotlight Stock Market: (REDW)
© 2021 Copyright Redwood Pharma.